Drug-releasing stents are used for percutaneous coronary interventions (PCI) to help reduce the rate of re-narrowing of a coronary artery. Approval of drug-eluting coronary stents was based on results of relatively small trials of selected patients; however, in routine practice, stents are used in a broader spectrum of patients.
Anders M. Galløe, M.D., of the University of Copenhagen, Denmark, and colleagues compared the efficacy and safety of sirolimus-eluting and paclitaxel-eluting stents in a study designed to reflect everyday clinical practice. The SORT OUT II trial included 2,098 men and women treated with PCI and randomized to receive either sirolimus-eluting or paclitaxel-eluting stents at five university hospitals in Denmark. The patients were initially treated for ST-segment elevation myocardial infarction, non-STEMI or unstable angina pectoris, and stable angina.
The researchers found that the proportion of patients experiencing major adverse cardiac events, such as cardiac death, heart attack, target lesion revascularization, or target vessel revascularization, were 98 for the sirolimus-eluting stent group and 114 for the paclitaxel-eluting stent group. The stent thrombosis rates were 27 in the sirolimus-eluting stent group and 30 in the paclitaxel-eluting stent group.
“In conclusion, the SORT OUT II trial found no statistical significant differences in the primary or secondary end points between the sirolimus-eluting stent and paclitaxel-eluting stent in everyday clinical practice among patients undergoing PCI for ST-segment elevation myocardial infarction, non–ST-segment elevation myocardial infarction or unstable angina pectoris, and stable angina,” the authors write.
MEDICA.de; Source: JAMA and Archives Journals